Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q
28 nov. 2023 17h15 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update
13 nov. 2023 16h05 HE
|
Cyclacel
- Cyclacel Expects to Release Updated Phase 1/2 Clinical and Biomarker Data with Oral Fadraciclib and Provide Safety, Efficacy and Putative Mechanism Update for Oral Plogosertib - - Management to...
Cyclacel Pharmaceuticals to Release Third Quarter 2023 Financial Results
07 nov. 2023 09h15 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update
09 août 2023 16h05 HE
|
Cyclacel
- Key Catalysts ahead with Multiple Value Generating Readouts-- Expects to Release Phase 1/2 Data with Oral Fadraciclib -- Signals of Single-agent Efficacy with Oral Plogosertib -- Management to Host...
Cyclacel Pharmaceuticals to Release Second Quarter 2023 Financial Results
03 août 2023 09h15 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update
11 mai 2023 16h05 HE
|
Cyclacel
- Key Catalysts ahead with multiple Value Generating Readouts -- Expects to Report Phase 1/2 Data Releases with Oral Fadraciclib -- Advancing single-agent Efficacy with Differentiated Oral Plogosertib...
Cyclacel Pharmaceuticals to Release First Quarter 2023 Financial Results
04 mai 2023 09h15 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals Announces Receipt of $4.7 Million R&D Tax Credit
03 mai 2023 09h15 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., May 03, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals to Participate in March Investor Conferences
07 mars 2023 09h15 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., March 07, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing...
Cyclacel Pharmaceuticals Reports Fourth Quarter And Full Year 2022 Financial Results And Provides Business Update
06 mars 2023 16h05 HE
|
Cyclacel
- On Track to Start Oral Fadraciclib Phase 2 Proof of Concept in 1H 2023 and Report Interim data in 2H 2023 - - Expect to Report Final Data from Fadraciclib 065-101 Dose Escalation - - Expect to...